Paragonix Technologies Sold to Getinge - Impact on Medical Device Innovation

Wednesday, 11 September 2024, 13:30

Paragonix Technologies, known for its innovative medical devices, has been sold to Getinge. This acquisition signifies a major shift in the medical device landscape, emphasizing the importance of organ preservation technology. With this sale, Paragonix aims to further enhance its contributions to healthcare.
LivaRava_Medicine_Default.png
Paragonix Technologies Sold to Getinge - Impact on Medical Device Innovation

Overview of the Sale

On October 1, 2023, Signet Healthcare Partners announced the successful sale of its portfolio company, Paragonix Technologies, to Getinge. This strategic acquisition enhances Getinge's capabilities in medical devices, specifically in organ preservation technology.

Importance of Organ Preservation

Organ preservation is crucial in the field of transplantation, ensuring that organs remain viable for recipients. Paragonix Technologies has been at the forefront of developing systems that improve the safety and efficiency of organ storage.

Impact on Healthcare Technology

  • Strengthens Getinge’s position in the healthcare sector.
  • Advances medical innovations in organ transplantation.
  • Enhances patient outcomes through improved organ preservation methods.

Future Directions

As part of the Getinge family, Paragonix is expected to expand its product offerings, further solidifying its commitment to healthcare innovations.


This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.


Related posts


Newsletter

Subscribe to our newsletter for the most accurate and current medical news. Stay updated and deepen your understanding of medical advancements effortlessly.

Subscribe